Daniela Chereches

What’s the real impact of the "one-and-done PI" in clinical trials? Some say it’s a major issue, while others question if it’s a concern at all. Clinical Leader Live’s expert panel—backed by research—dives into the data, debate, and potential solutions.

By Juliet Brown, PhD; Joan Busner, PhD; Daniela Chereches; MD, MBA; & Margot Oakley, RN, MSN Central Rating (CR) in clinical trials is a powerful approach to ensuring unbiased, reliable, and consistent data collection. However, misconceptions about its limitations often overshadow its benefits. CR's core objective is to enhance data validity through the involvement of independent raters, robust training, and streamlined processes that minimize cognitive biases and variability in assessments.

Webinar: Can We Enable Clinical Trial Operations Without Human-In-The-Loop? To drive forward the promising pipeline of breakthrough therapies while curbing costs, industry futurists are putting their bets on technological advancements and GenAI to reshape the drug development life cycle.